Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22717519 | 1.00 | KMT2A (0.62) | KMT2AMYCRBP4TTROPRK1 | |
| SCHEMBL28229508 | 0.81 | KMT2A (0.52) | KMT2AMYCRBP4TTROPRK1 | |
| SCHEMBL30417107 | 0.80 | FFAR2 (0.45) | FFAR2CDC7 | |
| SCHEMBL29574622 | 0.79 | KMT2A (0.65) | KMT2AMYCMEN1CYP1A2CYP3A4 | |
| SCHEMBL353809 | 0.79 | KMT2A (0.65) | KMT2AMYCMEN1CYP1A2CYP3A4 | |
| SCHEMBL31718061 | 0.79 | CHI3L1 (0.49) | FFAR2CDC7CHIA | |
| SCHEMBL10926941 | 0.77 | KMT2A (0.70) | KMT2AMYCRBP4TTRMEN1 | |
| SCHEMBL24297726 | 0.76 | KMT2A (0.68) | KMT2AMYCRBP4TTROPRK1 | |
| SCHEMBL16034182 | 0.76 | KMT2A (0.68) | KMT2AMYCRBP4TTROPRK1 | |
| SCHEMBL22717655 | 0.75 | KMT2A (0.59) | KMT2AMYCMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3976608-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | KMT2A 2910/4885MYC 1533/4885RBP4 4449/4885 |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | POLQ, POLK, POLA1 | KMT2A 2938/4885MYC 2800/4885RBP4 3974/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | KMT2A 2518/4885MYC 3495/4885RBP4 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.